Expression of the mucosal vascular addressin, MAdCAM-1, in inflammatory liver disease.
about
Sex hormones selectively impact the endocervical mucosal microenvironment: implications for HIV transmissionHepatic expression of secondary lymphoid chemokine (CCL21) promotes the development of portal-associated lymphoid tissue in chronic inflammatory liver diseasePathogenesis of primary sclerosing cholangitis and advances in diagnosis and managementDifferential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn's diseaseThe role of chemokines in the recruitment of lymphocytes to the liver.Association between chronic liver and colon inflammation during the development of murine syngeneic graft-versus-host diseaseRegulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity.Current research on the treatment of primary sclerosing cholangitis.Role of cell adhesion molecules in leukocyte recruitment in the liver and gut.Characterization of animal models for primary sclerosing cholangitis (PSC).Identification of a putative pathway for the muscle homing of stem cells in a muscular dystrophy modelLymphocyte recruitment to the liver: molecular insights into the pathogenesis of liver injury and hepatitis.Lymphocyte homing and its role in the pathogenesis of IBD.Lymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitis.Recent insights in primary sclerosing cholangitis.Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target.Emerging treatments for primary sclerosing cholangitis.Helicobacter-induced chronic active lymphoid aggregates have characteristics of tertiary lymphoid tissue.The effect of HIV infection and HCV viremia on inflammatory mediators and hepatic injury-The Women's Interagency HIV Study.New human microvascular endothelial cell lines with specific adhesion molecules phenotypes.The chemokine receptor CXCR5 is pivotal for ectopic mucosa-associated lymphoid tissue neogenesis in chronic Helicobacter pylori-induced inflammation.Mucosal addressin cell adhesion molecule-1 of rhesus macaques: molecular cloning, expression, and alteration after viral infection.Inflammatory cytokines induce MAdCAM-1 in murine hepatic endothelial cells and mediate alpha-4 beta-7 integrin dependent lymphocyte endothelial adhesion in vitro.Cutting edge issues in primary sclerosing cholangitis.Early treatment of SIV+ macaques with an α4β7 mAb alters virus distribution and preserves CD4+ T cells in later stages of infection.Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.Mucosal addressin cell adhesion molecule (MAdCAM-1) expression is upregulated in the cirrhotic liver and immunolocalises to the peribiliary plexus and lymphoid aggregates.Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease.
P2860
Q21090622-2797D50B-F06D-42E3-815C-960B067DF93EQ24669792-5CEAD6D3-ED69-4E08-BAA7-D4078B0EDC08Q27015831-DB3F6B87-9392-44A1-967E-6294AD4721F7Q28213091-C45C93EC-E579-42AF-BBB4-E590E6D1571BQ33906565-641C6F76-1D88-417A-982A-D999295B8B5CQ34178879-F8D4032A-C574-47AD-84C4-A668BFF0EB61Q34540056-AF890827-42CA-4ED8-963F-0A7E4033C386Q35066561-241C9DBF-8A81-4D47-A9E7-E640BBCAEDE3Q35106847-24D5FFB4-B4B4-4692-B8E9-5BD7CD0F6917Q35896870-E9422CC5-E1D5-4E4B-A10D-33BB7740B2A2Q36322999-7D751AA4-00ED-4A02-A76C-D3B17CE1F539Q37087991-6FFC3E94-6EA2-43B8-AF52-44D1B0C2DC9BQ37130397-8FB6590A-557C-4582-8045-0657606792E6Q37378198-0C053063-8BDF-44F4-9E3E-F491CA9F3142Q38019989-61658B82-8E6F-4E0C-882E-49D2605ED2C9Q38210630-CBF68D12-9C0F-4279-B199-5C4A65C6D83AQ38748384-6C5DE865-13A7-4FBE-80E4-EB8C16CA4D6FQ39755242-14D55DA4-665A-4C1C-B042-3265C951144DQ40043487-D389098A-2945-472F-87E2-A4F08CCD76EFQ40672427-413FDE97-3541-43E8-8979-2D905E6B9AB8Q42202704-57BF42C7-7B38-4850-BB8D-0A4F84A4CCF5Q42218744-BB3E9963-C596-49E3-8B79-70BD5F3293FAQ42237864-4D7D4F24-2763-4D4E-9335-4FBEF319409BQ44391213-D8768656-10BE-46AD-81D5-0229786995B4Q47551858-059E13BD-F865-4EC9-B596-760A95C21D81Q48151874-F126EEA0-0C5E-4BC9-B89C-5DDA80C85CE6Q50847998-2AF7E2FC-D568-4BA9-8B8F-7FE1030536E2Q52618987-B21856AE-7C74-41DF-AF2E-06541692632B
P2860
Expression of the mucosal vascular addressin, MAdCAM-1, in inflammatory liver disease.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Expression of the mucosal vascular addressin, MAdCAM-1, in inflammatory liver disease.
@en
type
label
Expression of the mucosal vascular addressin, MAdCAM-1, in inflammatory liver disease.
@en
prefLabel
Expression of the mucosal vascular addressin, MAdCAM-1, in inflammatory liver disease.
@en
P2093
P2860
P1433
P1476
Expression of the mucosal vascular addressin, MAdCAM-1, in inflammatory liver disease.
@en
P2093
Dhillon AP
Ferrell LD
Ferrier RK
MacSween RN
P2860
P304
P356
10.1111/J.1478-3231.1999.TB00084.X
P577
1999-12-01T00:00:00Z